{
    "id": 5940,
    "name": "malignant peripheral nerve sheath tumor",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5940",
    "evidence": [
        {
            "id": 1897,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a malignant peripheral nerve sheath tumor cell line harboring a PDGFRA amplification demonstrated cell growth inhibition when treated with Gleevec (imatinib) (PMID: 16357008).",
            "molecularProfile": {
                "id": 1417,
                "profileName": "PDGFRA amp"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2384,
                    "pubMedId": 16357008,
                    "title": "Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16357008"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4166,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in patients with malignant peripheral nerve sheath tumors (n=14) was suspended due to lack of drug activity (PMID: 26710211).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4408,
                    "pubMedId": 26710211,
                    "title": "SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26710211"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5029,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 were sensitive to XAV939 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 1732,
                "therapyName": "XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5030,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 were sensitive to IWR-1 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 2455,
                "therapyName": "IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5031,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, IWR-1 treatment resulted in a synergistic effect when combined with Afinitor (everolimus), inducing apoptosis of malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 3733,
                "therapyName": "Everolimus + IWR-1",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5032,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, XAV939 treatment resulted in a synergistic effect when combined with Afinitor (everolimus), inducing apoptosis of malignant peripheral nerve sheath tumor cells harboring EIF3E-RSPO2 (PMID: 23535903).",
            "molecularProfile": {
                "id": 18335,
                "profileName": "EIF3E - RSPO2"
            },
            "therapy": {
                "id": 3734,
                "therapyName": "Everolimus + XAV939",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4843,
                    "pubMedId": 23535903,
                    "title": "Canonical Wnt/\u03b2-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23535903"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6002,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant peripheral nerve sheath cell line xenograft models treated with Afinitor (everolimus) demonstrated a 76% decrease in tumor growth (PMID: 18483311).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5220,
                    "pubMedId": 18483311,
                    "title": "Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18483311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 8315,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Alisertib (MLN8237) treatment resulted in twelve-week progression free survival in 60% (6/10) of malignant peripheral nerve sheath tumor patients (PMID: 27502708).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 626,
                "therapyName": "Alisertib",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6602,
                    "pubMedId": 27502708,
                    "title": "Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27502708"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11766,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Selinexor (KPT-330) and Kyprolis (carfilzomib) resulted in downregulation of Birc5 (Survivin) and enhanced induction of apoptotic markers compared to Selinexor (KPT-330) alone, and worked additively to decrease viability of malignant peripheral nerve sheath tumor (MPNST) cells in culture, and resulted in enhanced tumor growth inhibition in MPNST xenograft models (PMID: 28314790).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6143,
                "therapyName": "Carfilzomib + Selinexor",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9766,
                    "pubMedId": 28314790,
                    "title": "Selinexor (KPT-330) Induces Tumor Suppression through Nuclear Sequestration of I\u03baB and Downregulation of Survivin.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28314790"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16550,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) demonstrated safety and preliminary efficacy, resulted in stable disease as best overall response in a patients with malignant peripheral nerve sheath tumor (PMID: 30724423).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14616,
                    "pubMedId": 30724423,
                    "title": "Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30724423"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 18450,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Keytruda (pembrolizumab) treatment resulted in complete metabolic response after 4 cycles of treatment in a patient with CD274 (PD-L1)-positive malignant peripheral nerve sheath tumor, and the patient stayed on treatment for 21 cycles (PMID: 31383651).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 5940,
                "name": "malignant peripheral nerve sheath tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16190,
                    "pubMedId": 31383651,
                    "title": "PD-1 Inhibition Achieves a Complete Metabolic Response in a Patient with Malignant Peripheral Nerve Sheath Tumor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31383651"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT02301039",
            "title": "A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02372006",
            "title": "Trial of Afatinib in Pediatric Tumours",
            "phase": "Phase Ib/II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584309",
            "title": "Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5153,
                    "therapyName": "Dexrazoxane",
                    "synonyms": null
                },
                {
                    "id": 4140,
                    "therapyName": "Doxorubicin + Olaratumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02584647",
            "title": "Combination of PLX3397 and Sirolimus in Unresectable Sarcoma (Phase 1) and Malignant Peripheral Nerve Sheath Tumors (Phase 2)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3155,
                    "therapyName": "Pexidartinib + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02601209",
            "title": "Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                },
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02639546",
            "title": "Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors (iMATRIXcobi)",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1004,
                    "therapyName": "Cobimetinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02978859",
            "title": "MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1655,
                    "therapyName": "MGCD516",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02986919",
            "title": "Study of CPI-0610 in Patients With Malignant Peripheral Nerve Sheath Tumors",
            "phase": "Phase II",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 2033,
                    "therapyName": "CPI-0610",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02987959",
            "title": "Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1282,
                    "therapyName": "Sapanisertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03009201",
            "title": "Ribociclib and Doxorubicin Hydrochloride in Treating Patients Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5179,
                    "therapyName": "Doxorubicin + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03433183",
            "title": "SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 8591,
                    "therapyName": "Selumetinib + Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03872427",
            "title": "Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, CB-839 HCl, Anti-Cancer Treatment, BeGIN Study",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1667,
                    "therapyName": "CB-839",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03880123",
            "title": "Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma",
            "phase": "Phase I",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 8089,
                    "therapyName": "Ixazomib + Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04028063",
            "title": "Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9314,
                    "therapyName": "AGEN1884 + AGEN2034 + Doxorubicin",
                    "synonyms": null
                }
            ]
        }
    ]
}